This is a Phase I study of HIV-infected subjects age 2-12 years, who have been maintained on antiretroviral therapy for > 6 months, whose CD4 count is > 200 were given HIVIG, randomized to 1 of 3 doses. Six monthly infusions were given, then a 3 month, and monthly follow-up visits. The objectives of this study are to evaluate the safety and tolerance; evaluate dosage by serial measurements of IgG, P-24 antigen and rubella antibody titers; and to evaluate antiviral activity of HIVIG by assays of viral burden. The study has been closed.
Showing the most recent 10 out of 638 publications